181 related articles for article (PubMed ID: 33817854)
1. Safety comparison of therapies used in inflammatory bowel disease.
Pudipeddi A
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():20-21. PubMed ID: 33817854
[No Abstract] [Full Text] [Related]
2. Advanced therapies in inflammatory bowel disease: Special considerations.
Williams AJ
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():22-24. PubMed ID: 33817851
[No Abstract] [Full Text] [Related]
3. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary.
Mountifield R
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():25-26. PubMed ID: 33817852
[No Abstract] [Full Text] [Related]
4. Next-Generation Therapeutics for Inflammatory Bowel Disease.
Dulai PS; Sandborn WJ
Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head trials in inflammatory bowel disease.
Radford-Smith G
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():18-19. PubMed ID: 33817853
[No Abstract] [Full Text] [Related]
6. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
7. The current state of comparative effectiveness research in inflammatory bowel disease.
Dulai PS
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():16-17. PubMed ID: 33817857
[No Abstract] [Full Text] [Related]
8. Managing Risks with Biologics.
Click B; Regueiro M
Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
[TBL] [Abstract][Full Text] [Related]
9. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
Chang S; Hudesman D
Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
[TBL] [Abstract][Full Text] [Related]
10. Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
Raine T; Verstockt B; De Cruz P
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):794-796. PubMed ID: 32818453
[No Abstract] [Full Text] [Related]
11. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
van Langenberg DR
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
[No Abstract] [Full Text] [Related]
12. Biologic therapy in inflammatory bowel disease.
Loftus EV
Gastroenterol Clin North Am; 2014 Sep; 43(3):xv-xvii. PubMed ID: 25110264
[No Abstract] [Full Text] [Related]
13. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
17. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
19. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
20. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
